Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Meiri, E; Garrett-Mayer, E; Halabi, S; Mangat, PK; Shrestha, S; Ahn, ER; Osayameh, O; Perla, V; Schilsky, RL

Published Date

  • February 1, 2020

Published In

Volume / Issue

  • 38 / 4

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X